2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Dihydroorotate Dehydrogenase

Dihydroorotate Dehydrogenase

DHODH

Dihydroorotate Dehydrogenase

Related Products

PDF 0.6 MB

Dihydroorotate dehydrogenase (DHODH) is the fourth enzyme in the de novo pyrimidine biosynthesis pathway, serving as the catalyst to oxidize the dihydroorotate to orotic acid in the biosynthesis of uridine monophosphate (UMP). DHODH is a known target for autoimmune diseases as well as an important target for malaria.

Based on localization and electron acceptor, DHODHs have classified into two families: Family 1 members are soluble proteins localized to the cytosol, while family 2 members are membrane proteins localized to the inner mitochondrial membrane. Family 1 is further subdivided into family 1A and family 1B, which use fumarate and NAD+ (respectively) as electron acceptors. Family 2 DHODH enzymes use respiratory quinones as electron acceptors.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-135282
    DHODH-IN-1
    		Inhibitor 98.65%
    DHODH-IN-1 (compound 18d) is a potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC50 of 25 nM. DHODH-IN-1 is an inhibitor of pyrimidine biosynthesis pathway.
    DHODH-IN-1
  • HY-101813
    Laflunimus
    		Inhibitor 99.70%
    Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor.
    Laflunimus
  • HY-153112
    DHODH-IN-23
    		Inhibitor 98.75%
    DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.
    DHODH-IN-23
  • HY-110159
    (E/Z)-Teriflunomide
    		Inhibitor 99.87%
    (E/Z)-Teriflunomide ((E/Z)-A77 1726) is the active metabolite of Leflunomide (HY-B0083). Leflunomide is an immunomodulatory agent that may exert effects by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH). Leflunomide can be used for the research of rheumatoid arthritis (RA).
    (E/Z)-Teriflunomide
  • HY-132170
    DSM502
    		Inhibitor 99.74%
    DSM502 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM502 exhibits nanomolar potency againsts Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs.
    DSM502
  • HY-135570
    hDHODH-IN-3
    		Inhibitor 99.97%
    hDHODH-IN-3 (compound 21d) is a human dihydroorotate dehydrogenase (HsDHODH) inhibitor, inhibits measles virus replication with a pMIC50 value of 8.6.
    hDHODH-IN-3
  • HY-W015495R
    L-Dihydroorotic acid (Standard)
    		Substrate
    L-Dihydroorotic acid (Standard) is an analytical reference standard for L-Dihydroorotic acid. This product is used for research and analytical applications. L-Dihydroorotic acid is an important intermediate in the metabolism of orotic acid and a substrate of dihydroorotate dehydrogenase (DHODH). L-Dihydroorotic acid can reversibly hydrolyze to yield the acyclic L-ureidosuccinic acid by dihydrowhey enzyme.
    L-Dihydroorotic acid (Standard)
  • HY-149642
    hDHODH-IN-13
    		Inhibitor 99.97%
    hDHODH-IN-13 (compound w2) is an inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 value of 173.4 nM. hDHODH-IN-13 can be used in the research of IBD.
    hDHODH-IN-13
  • HY-110159S
    Teriflunomide-d4
    		99.98%
    Teriflunomide-d4 is deuterium labeled Teriflunomide.
    Teriflunomide-d<sub>4</sub>
  • HY-132171A
    DSM705 hydrochloride
    		Inhibitor 99.56%
    DSM705 hydrochloride, an orally active antimalarial compound, is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM705 hydrochloride exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites (IC50=95, 52 nM for P. falciparum and P. vivax DHODH, respectively), with no inhibition of mammalian DHODHs.
    DSM705 hydrochloride
  • HY-132174
    CHIKV-IN-2
    		Inhibitor 99.21%
    CHIKV-IN-2 is a potent inhibitor against Chikungunya virus (CHIKV), with excellent cellular antiviral activity (EC90=270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular target Dihydroorotate Dehydrogenase (DHODH), which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools.
    CHIKV-IN-2
  • HY-135664
    hDHODH-IN-5
    		Inhibitor 98.55%
    DHODH-IN-7 is a human dihydroorotate dehydrogenase (DHODH) inhibitor, with an IC50 of 0.91 μM. DHODH-IN-7 induces differentiation in acute myeloid leukemia.
    hDHODH-IN-5
  • HY-N7961
    (E/Z)-Ginkgolic acid C17:2
    		Inhibitor 99.37%
    (E/Z)-Ginkgolic acid C17:2, isolated from Ginkgo biloba, can bind with human dihydroorotate dehydrogenase (DHODH) tightly.
    (E/Z)-Ginkgolic acid C17:2
  • HY-N3097
    Pellitorine
    		Agonist 99.84%
    Pellitorine is a bioactive natural amide compound. Pellitorine can competitively antagonize the activation of TRPV1 by Capsaicin (HY-10448), thereby reducing pain signal transmission. Pellitorine improves cognitive dysfunction by upregulating the BDNF-ERK1/2-CREB and Nrf2-HO-1 pathways. Pellitorine exerts anti-inflammatory and anti-sepsis effects by inhibiting the release of high mobility group protein B1 (HMGB1) and the expression of RAGE/TLR4. Pellitorine exerts its antithrombotic effect by prolonging the clotting time, inhibiting the activity of clotting factors and thrombin. Pellitorine inhibits lipid peroxidation and resists ferroptosis by upregulating GPX4 and DHODH. Pellitorine kills Aedes aegypti mosquito larvae by inhibiting V-type H⁺-ATPase and aquaporin 4 (AaAQP4). Pellitorine exhibits anti-cancer activity (e.g., leukemia and breast cancer) and has inhibitory effects on certain bacteria.
    Pellitorine
  • HY-135678
    DHODH-IN-14
    		Inhibitor 99.81%
    DHODH-IN-14 (Compound 7l) is a hydroxyfurazan analog of A771726. DHODH-IN-14 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 0.49 μM for rat liver DHODH. DHODH-IN-14 can be used for rheumatoid arthritis.
    DHODH-IN-14
  • HY-135658
    hDHODH-IN-1
    		Inhibitor 99.90%
    hDHODH-IN-1 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor. hDHODH-IN-1 has anti-inflammatory effect.
    hDHODH-IN-1
  • HY-128787
    hDHODH-IN-4
    		Inhibitor 99.73%
    hDHODH-IN-4 is a potent human dihydroorotate dehydrogenase (DHODH) inhibitor, with a pIC50 of 7.8 for human recombinant DHODH. hDHODH-IN-4 inhibits measles virus replication, with a pMIC50 of 8.8.
    hDHODH-IN-4
  • HY-135675
    DHODH-IN-11
    		Inhibitor 99.69%
    DHODH-IN-11 (Compound 14b) is a Leflunomide derivative and a weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.03.
    DHODH-IN-11
  • HY-W078844
    PfDHODH-IN-2
    		Inhibitor 99.83%
    PfDHODH-IN-2, a dihydrothiophenone derivative (Compound 11), is a potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor with an IC50 of 1.11 µM. PfDHODH-IN-2 acts as an antimalarial agent and can be used for the research of malaria.
    PfDHODH-IN-2
  • HY-145261
    hDHODH-IN-8
    		Inhibitor
    hDHODH-IN-8 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 16 nM. hDHODH-IN-8 has potent antiproliferative activity and excellent aqueous solubility. hDHODH-IN-8 has the potential for the research of tumor disease, especially lymphoma.
    hDHODH-IN-8
Cat. No. Product Name / Synonyms Application Reactivity